Clinical trial
Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS
NCT00334074 · Baylor Research Institute, Other · Completed
Key facts
| NCT number | NCT00334074 |
|---|---|
| Title | Clofarabine and Ara-C for the Treatment of Relapsed AML and Untreated MDS |
| Official title | Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in Selected Elderly Patients at High Risk of Anthracycline Toxicity |
| Lead sponsor | Baylor Research Institute, Other |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Clofarabine and Cytarabine |
| Enrollment | 30 |
| Start date | Aug 1, 2005 |
| Primary completion | Feb 1, 2007 |
| Completion | Feb 1, 2008 |
| First posted | Jun 6, 2006 |
| Last update posted | Jul 17, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: